The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review.

ABSTRACT:

Background and objective

Immune checkpoint inhibitors (ICIs) have been widely applied and studied in the treatment of gastrointestinal (GI) cancers, and have achieved good results. However, in clinical practice, it has been observed that only some patients respond well to ICIs, and some patients may experience various degrees of adverse reactions during the treatment. Timely evaluation of the potential therapeutic effects and adverse reactions of ICIs for patients has important clinical significance. This review aimed to summarize recent progress regarding efficacy-associated biomarkers for ICIs in GI cancer.

Methods

The literature on ICI treatment in GI cancers was searched in the PubMed, Embase, and Cochrane Library databases for publications up to April 2023.

Key conte

SUBMITTER: Zhao P 

PROVIDER: S-EPMC10932650 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature